Specify a stock or a cryptocurrency in the search bar to get a summary
Ion Beam Applications SA
IBABIon Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium. Address: 3, Chemin du Cyclotron, Louvain-la-Neuve, Belgium, 1348
Analytics
WallStreet Target Price
14.52 EURP/E ratio
44.5185Dividend Yield
1.39 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IBAB
Dividend Analytics IBAB
Dividend growth over 5 years
–Continuous growth
1 yearPayout Ratio 5 years average
33 %Dividend History IBAB
Stock Valuation IBAB
Financials IBAB
Results | 2019 | Dynamics |